A Phase 1/2 interventional study of Panitumumab and Motesanib diphosphate in Lung Cancer and Non-Small Cell Lung Cancer, sponsored by Amgen. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-03-24.
Sponsored by Amgen · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies testing panitumumab in Carcinoma, Non-Small-Cell Lung — none open to participants now, none under way, none of them phase 3. Panitumumab · Carcinoma, Non-Small-Cell Lung.
Among the 11 studies testing panitumumab in Carcinoma, Non-Small-Cell Lung, this one is the 5th largest by enrollment of the 10 interventional ones that give a count, is the only one that started in 2005, is the only one in phase 1/2, and was the 3rd registered.
7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.
Browse Carcinoma, Non-Small-Cell Lung studies →None of the 11 studies testing panitumumab in Carcinoma, Non-Small-Cell Lung is open now. The open studies under Carcinoma, Non-Small-Cell Lung, anywhere →
Panitumumab: first FDA approval 2006 (VECTIBIX), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 8
First in 2000; this study’s year is marked. 1 started in 2005.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 51 is below the median of 62 across 6,024 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.
Median enrollment 51 across the 10 interventional studies. Of the 9 that completed or were terminated, 3 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 11 have an industry lead sponsor. The 7 most frequent:
Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
40 studies in Carcinoma, Non-Small-Cell Lung by Amgen: 2 open now, 7 under way, 4 of them phase 3. Of 27 finished, 13 (48%) have results posted.
Among the 40 studies in Carcinoma, Non-Small-Cell Lung by Amgen, this one is the 20th largest by enrollment of the 31 interventional ones that give a count, is the only one that started in 2005, is one of 5 in phase 1/2, and was the 5th registered.
Amgen’s Carcinoma, Non-Small-Cell Lung studies by the year they started, since 1999.
None of the studies under way reaches primary completion within a year.
Among the 11 studies testing panitumumab in Carcinoma, Non-Small-Cell Lung, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Amgen’s 40 in Carcinoma, Non-Small-Cell Lung:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this trial is: - To characterize the safety profile of motesanib when used in combination with carboplatin/paclitaxel (CP), with panitumumab or with CP and panitumumab in patients with advanced non-small cell lung cancer (NSCLC). - To establish the pharmacokinetic (PK) profile of motesanib when it is used in combination with CP, with panitumumab, or with CP and panitumumab. - To compare the paclitaxel and motesanib PK profiles when the medications are administered 30 minutes (min) or approximately 48 hours (hrs) apart. - To characterize the panitumumab and paclitaxel exposure in the combination regimens of motesanib with CP, motesanib with panitumumab, or motesanib with CP and panitumumab. - To describe the objective response rate (ORR) in each dose cohort. - To measure the immunogenicity of panitumumab in patients administered motesanib with panitumumab and motesanib with CP and panitumumab.
This was a multicenter, open-label, dose-finding clinical trial examining the safety and PK of once or twice daily motesanib administered with CP or with CP and panitumumab in chemotherapy naïve patients, and with panitumumab in patients with no more than one prior chemotherapy regimen for NSCLC.
Participants were enrolled into the Panitumumab + Paclitaxel + Carboplatin + Motesanib once a safe and tolerable dose of AMG 706 was established in the other treatment arms.
7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.
This study's enrollment of 51 is below the median of 62 across 6,024 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.
Browse Carcinoma, Non-Small-Cell Lung studies →Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
Compared within Carcinoma, Non-Small-Cell Lung, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Lung Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Chemotherapy naïve participants received paclitaxel 200 mg/m\^2 and carboplatin chemotherapy administered by intravenous (IV) infusion on Day 1 of each 21-day cycle, and motesanib, orally self-administered on Days 3-21 of Cycle 1 and then on Days 1 to 21 of Cycle 2 and all cycles thereafter. The initial dose of motesanib was 50 mg once daily administered in the initial cohort and up to 125 mg once daily was used in subsequent cohorts. A cycle was defined as the 3 weeks plus the time to recover from toxicity, if encountered.
Drug: Motesanib diphosphate · Drug: Paclitaxel · Drug: Carboplatin
Participants with no more than one prior chemotherapy regimen for NSCLC received panitumumab administered by IV at 9.0 mg/kg on Day 1 of each 21-day cycle, and motesanib, orally self-administered on Days 3-21 of Cycle 1 and then on Days 1 to 21 of Cycle 2 and all cycles thereafter. The initial dose of motesanib was 50 mg once daily administered in the initial cohort, up to 125 mg once daily was used in subsequent cohorts.
Biological: Panitumumab · Drug: Motesanib diphosphate
Chemotherapy naïve participants received panitumumab administered by IV at 9.0 mg/kg on Day 1 of each 21-day cycle, paclitaxel 200 mg/m\^2 and carboplatin chemotherapy administered by IV infusion on Day 1 of each 21-day cycle, and motesanib, orally self-administered on Days 3-21 of Cycle 1 and then on Days 1 to 21 of Cycle 2 and all cycles thereafter. Participants were enrolled in this arm once a safe and tolerable dose of motesanib was established.
Biological: Panitumumab · Drug: Motesanib diphosphate · Drug: Paclitaxel · Drug: Carboplatin
9.0 mg/kg on Day 1 of each 21-day cycle administered by intravenous infusion over approximately 60 minutes.
Also known as: Vectibix, ABX-EGF
Dose-finding with an initial dose of 50 mg once daily and up to 125 mg once daily. 75 mg twice daily was also to be tested.
Also known as: AMG 706
Paclitaxel 200 mg/m\^2 administered by IV infusion over 3 hours.
Carboplatin was administered IV over approximately 30 minutes. Carboplatin was dosed using the glomerular filtration rate (GFR) and Calvert formula to AUC/time curve of 6 mg/mL×min.
Time to Maximum Plasma Concentration of Motesanib (Tmax) for Cycle 1
The time after dosing that the maximal plasma concentration of motesanib was observed in Cycle 1. For the 75 mg BID cohorts, Tmax is reported for the first daily dose.
Time frame: Cycle 1, Day 3 at predose, 15 and 30 minutes, and at 1, 2, 4, 6, 10 (QD cohorts only), and 24 hours post-dose.
Maximum Observed Plasma Concentration of Motesanib (Cmax) in Cycle 1
The maximal observed plasma concentration of motesanib after a single dose dose in Cycle 1. For the 75 mg BID cohorts, Cmax is reported for the first daily dose.
Time frame: Cycle 1, Day 3 at predose, 15 and 30 min, and at 1, 2, 4, 6, 10 (QD cohorts only), and 24 hours post-dose.
Estimated Terminal-phase Half-life (t1/2,z) of Motesanib in Cycle 1
The terminal-phase elimination half-life (t1/2,z) of motesanib was calculated as ln(2)/λz. The terminal elimination rate constant (λz) was determined by linear regression of the natural logarithms of at least the last 3 measurable concentrations during the terminal phase. For the 75 mg BID cohorts, t1/2,z is reported for the first daily dose.
Time frame: Cycle 1, Day 3 at predose, 15 and 30 min, and at 1, 2, 4, 6, 10 (QD cohorts only), and 24 hours postdose.
Area Under the Plasma Concentration-time Curve for Motesanib in Cycle 1
Area under the plasma concentration-time curve for motesanib in Cycle 1 calculated using the using the linear/log trapezoidal method. AUC from time zero to infinity (AUC0-inf) is reported for the 50 and 125 mg QD cohorts and AUC from time 0 to 24 hours post-dose (AUC0-24) is reported for the 75 mg BID cohort, where AUC0-24 is the sum of AUC0-12 for the first and second daily dose.
Time frame: Cycle 1, Day 3 at predose, 15 and 30 minutes, and at 1, 2, 4, 6, 10 (QD cohorts only), and 24 hours post-dose.
Trough Plasma Concentration at 24 Hours Post-dose (C24) for Motesanib in Cycle 1
The trough plasma concentration for motesanib at 24 hours postdose in Cycle 1. For the 75 BID cohort, C24 is the observed concentration at 24 hours (ie, after the second daily dose).
Time frame: Cycle 1, Day 3, 24 hours post-dose
Time to Maximum Plasma Concentration of Motesanib (Tmax) in Cycle 2
The time after dosing that the maximal plasma concentration of motesanib was observed in Cycle 2. For the 75 mg BID cohorts, Tmax is reported for the first daily dose.
Time frame: Cycle 2, Day 1 at predose, 15 and 30 min, and at 1, 2, 4, 6, 10 (QD cohorts only), and 24 hours post-dose.
Maximum Observed Plasma Concentration of Motesanib (Cmax) in Cycle 2
The maximal observed plasma concentration of motesanib in Cycle 2, after multiple doses. For the 75 mg BID cohorts, Cmax is reported for the first daily dose.
Time frame: Cycle 2, Day 1 at predose, 15 and 30 min, and at 1, 2, 4, 6, 10 (QD cohorts only), and 24 hours post-dose.
Estimated Terminal-phase Half-life (t1/2,z) of Motesanib in Cycle 2
The terminal-phase elimination half-life (t1/2,z) of motesanib was calculated as ln(2)/λz. The terminal elimination rate constant (λz) was determined by linear regression of the natural logarithms of at least the last 3 measurable concentrations during the terminal phase. For the 75 mg BID cohorts, t1/2,z is reported for the first daily dose.
Time frame: Cycle 2, Day 1 at predose, 15 and 30 min, and at 1, 2, 4, 6, 10 (QD cohorts only), and 24 hours post-dose.
Area Under the Plasma Concentration-time Curve From Time 0 to 24 Hours Post-dose for Motesanib in Cycle 2
Area under the plasma concentration-time curve from time 0 to 24 hours post-dose (AUC0-24) for motesanib in Cycle 2 calculated using the using the linear/log trapezoidal method. For the 75 mg BID cohort AUC0-24 is the sum of AUC0-12 for the first and second daily dose.
Time frame: Cycle 2, Day 1 at predose, 15 and 30 minutes, and at 1, 2, 4, 6, 10 (QD cohorts only), and 24 hours post-dose.
Trough Plasma Concentration at 24 Hours Post-dose (C24) for Motesanib in Cycle 2
The trough plasma concentration for motesanib at 24 hours postdose in Cycle 2. For the 75 BID cohort, C24 is the observed concentration at 24 hours (ie, after the second daily dose).
Time frame: Cycle 2, Day 1, 24 hours post-dose
Percentage of Participants With an Overall Objective Response
Confirmed objective tumor response defined as a complete response (CR) or partial response (PR) using modified Response Evaluation Criteria in Solid Tumors (RECIST) version 1.0. Tumor response was evaluated by computed tomography (CT) scan or magnetic resonance imaging (MRI). Responding disease (CR or PR) was confirmed no less than 4 weeks after the criteria for response were first met. A complete response defined as the disappearance of all target lesions and all non-target lesions, no new lesions and normalization of tumor marker level. Partial response defined as either the disappearance of all target lesions and the persistence of one or more non-target lesion(s) or/and maintenance of tumor marker level above the normal limits, or, at least a 30% decrease in the sum of the longest diamer (LD) of target lesions, taking as reference the baseline sum LD and no new lesions and/or unequivocal progression of existing non-target lesions.
Time frame: After 9 weeks of treatment (at the end of Cycle 3)
Participants were enrolled from 18 January 2005 through 25 September 2006
| Milestone | Paclitaxel/Carboplatin + Motesanib 50 mg QD | Paclitaxel/Carboplatin + Motesanib 125 mg QD | Paclitaxel/Carboplatin + Motesanib 75 mg BID | Panitumumab + Motesanib 50 mg QD | Panitumumab + Motesanib 125 mg QD | Panitumumab + Motesanib 75 mg BID | Panitumumab + Paclitaxel/Carboplatin + Motesanib 125 mg QD |
|---|---|---|---|---|---|---|---|
| Started | 9 | 11 | 7 | 5 | 7 | 6 | 6 |
| Treated with motesanib | 6 | 11 | 6 | 4 | 7 | 5 | 6 |
| Completed | 5 | 8 | 4 | 4 | 3 | 3 | 4 |
| Not completed | 4 | 3 | 3 | 1 | 4 | 3 | 2 |
| Withdrew: Physician decision | 1 | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Death | 1 | 0 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Non-compliance | 1 | 2 | 2 | 0 | 2 | 2 | 1 |
| Withdrew: Other | 1 | 1 | 1 | 1 | 0 | 0 | 0 |
The time after dosing that the maximal plasma concentration of motesanib was observed in Cycle 1. For the 75 mg BID cohorts, Tmax is reported for the first daily dose.
| hours | Paclitaxel/Carboplatin + Motesanib 50 mg QD | Paclitaxel/Carboplatin + Motesanib 125 mg QD | Paclitaxel/Carboplatin + Motesanib 75 mg BID | Panitumumab + Motesanib 50 mg QD | Panitumumab + Motesanib 125 mg QD | Panitumumab + Motesanib 75 mg BID | Panitumumab + Paclitaxel/Carboplatin + Motesanib 125 mg QD |
|---|---|---|---|---|---|---|---|
| Time to Maximum Plasma Concentration of Motesanib (Tmax) for Cycle 1 | 0.75 (0.5 to 2.0) | 1.0 (0.5 to 6.0) | 0.75 (0.25 to 1.00) | 1.5 (0.5 to 4.0) | 1.0 (0.5 to 1.0) | 0.58 (0.50 to 1.00) | 1.0 (1.0 to 4.0) |
Confirmed objective tumor response defined as a complete response (CR) or partial response (PR) using modified Response Evaluation Criteria in Solid Tumors (RECIST) version 1.0. Tumor response was evaluated by computed tomography (CT) scan or magnetic resonance imaging (MRI). Responding disease (CR or PR) was confirmed no less than 4 weeks after the criteria for response were first met. A complete response defined as the disappearance of all target lesions and all non-target lesions, no new lesions and normalization of tumor marker level. Partial response defined as either the disappearance of all target lesions and the persistence of one or more non-target lesion(s) or/and maintenance of tumor marker level above the normal limits, or, at least a 30% decrease in the sum of the longest diamer (LD) of target lesions, taking as reference the baseline sum LD and no new lesions and/or unequivocal progression of existing non-target lesions.
| Percentage of participants | Paclitaxel/Carboplatin + Motesanib 50 mg QD | Paclitaxel/Carboplatin + Motesanib 125 mg QD | Paclitaxel/Carboplatin + Motesanib 75 mg BID | Panitumumab + Motesanib 50 mg QD | Panitumumab + Motesanib 125 mg QD | Panitumumab + Motesanib 75 mg BID | Panitumumab + Paclitaxel/Carboplatin + Motesanib 125 mg QD |
|---|---|---|---|---|---|---|---|
| Percentage of Participants With an Overall Objective Response | 33 | 18 | 0 | 0 | 0 | 0 | 17 |
The maximal observed plasma concentration of motesanib after a single dose dose in Cycle 1. For the 75 mg BID cohorts, Cmax is reported for the first daily dose.
| ng/mL | Paclitaxel/Carboplatin + Motesanib 50 mg QD | Paclitaxel/Carboplatin + Motesanib 125 mg QD | Paclitaxel/Carboplatin + Motesanib 75 mg BID | Panitumumab + Motesanib 50 mg QD | Panitumumab + Motesanib 125 mg QD | Panitumumab + Motesanib 75 mg BID | Panitumumab + Paclitaxel/Carboplatin + Motesanib 125 mg QD |
|---|---|---|---|---|---|---|---|
| Maximum Observed Plasma Concentration of Motesanib (Cmax) in Cycle 1 | 158 ± 55 | 525 ± 250 | 448 ± 112 | 328 ± 214 | 444 ± 130 | 198 ± 55 | 360 ± 243 |
The terminal-phase elimination half-life (t1/2,z) of motesanib was calculated as ln(2)/λz. The terminal elimination rate constant (λz) was determined by linear regression of the natural logarithms of at least the last 3 measurable concentrations during the terminal phase. For the 75 mg BID cohorts, t1/2,z is reported for the first daily dose.
| hours | Paclitaxel/Carboplatin + Motesanib 50 mg QD | Paclitaxel/Carboplatin + Motesanib 125 mg QD | Paclitaxel/Carboplatin + Motesanib 75 mg BID | Panitumumab + Motesanib 50 mg QD | Panitumumab + Motesanib 125 mg QD | Panitumumab + Motesanib 75 mg BID |
|---|---|---|---|---|---|---|
| Estimated Terminal-phase Half-life (t1/2,z) of Motesanib in Cycle 1 | 7.34 ± 2.07 | 5.33 ± 1.05 | 5.77 ± 1.45 | 6.47 ± 2.31 | 7.57 ± 2.60 | 8.28 ± 2.62 |
Area under the plasma concentration-time curve for motesanib in Cycle 1 calculated using the using the linear/log trapezoidal method. AUC from time zero to infinity (AUC0-inf) is reported for the 50 and 125 mg QD cohorts and AUC from time 0 to 24 hours post-dose (AUC0-24) is reported for the 75 mg BID cohort, where AUC0-24 is the sum of AUC0-12 for the first and second daily dose.
| μg*hr/mL | Paclitaxel/Carboplatin + Motesanib 50 mg QD | Paclitaxel/Carboplatin + Motesanib 125 mg QD | Paclitaxel/Carboplatin + Motesanib 75 mg BID | Panitumumab + Motesanib 50 mg QD | Panitumumab + Motesanib 125 mg QD | Panitumumab + Motesanib 75 mg BID |
|---|---|---|---|---|---|---|
| Area Under the Plasma Concentration-time Curve for Motesanib in Cycle 1 | 0.971 ± 0.300 | 3.21 ± 1.12 | 2.91 ± 1.01 | 1.74 ± 0.63 | 3.23 ± 1.83 | 2.04 ± 1.06 |
The trough plasma concentration for motesanib at 24 hours postdose in Cycle 1. For the 75 BID cohort, C24 is the observed concentration at 24 hours (ie, after the second daily dose).
| ng/mL | Paclitaxel/Carboplatin + Motesanib 50 mg QD | Paclitaxel/Carboplatin + Motesanib 125 mg QD | Paclitaxel/Carboplatin + Motesanib 75 mg BID | Panitumumab + Motesanib 50 mg QD | Panitumumab + Motesanib 125 mg QD | Panitumumab + Motesanib 75 mg BID |
|---|---|---|---|---|---|---|
| Trough Plasma Concentration at 24 Hours Post-dose (C24) for Motesanib in Cycle 1 | 9.12 ± 4.17 | 26.5 ± 16.8 | 56.7 ± 27.4 | 14.0 ± 11.7 | 32.5 ± 21.5 | 56.8 ± 21.1 |
The time after dosing that the maximal plasma concentration of motesanib was observed in Cycle 2. For the 75 mg BID cohorts, Tmax is reported for the first daily dose.
| hours | Paclitaxel/Carboplatin + Motesanib 50 mg QD | Paclitaxel/Carboplatin + Motesanib 125 mg QD | Paclitaxel/Carboplatin + Motesanib 75 mg BID | Panitumumab + Motesanib 50 mg QD | Panitumumab + Motesanib 125 mg QD | Panitumumab + Motesanib 75 mg BID | Panitumumab + Paclitaxel/Carboplatin + Motesanib 125 mg QD |
|---|---|---|---|---|---|---|---|
| Time to Maximum Plasma Concentration of Motesanib (Tmax) in Cycle 2 | 1.5 (1.0 to 2.0) | 1.0 (0.5 to 4.0) | 0.63 (0.25 to 4.0) | 1.0 (0.5 to 2.0) | 0.75 (0.25 to 2.0) | 1.0 (0.50 to 2.0) | 2.0 (0.5 to 2.0) |
The maximal observed plasma concentration of motesanib in Cycle 2, after multiple doses. For the 75 mg BID cohorts, Cmax is reported for the first daily dose.
| ng/mL | Paclitaxel/Carboplatin + Motesanib 50 mg QD | Paclitaxel/Carboplatin + Motesanib 125 mg QD | Paclitaxel/Carboplatin + Motesanib 75 mg BID | Panitumumab + Motesanib 50 mg QD | Panitumumab + Motesanib 125 mg QD | Panitumumab + Motesanib 75 mg BID | Panitumumab + Paclitaxel/Carboplatin + Motesanib 125 mg QD |
|---|---|---|---|---|---|---|---|
| Maximum Observed Plasma Concentration of Motesanib (Cmax) in Cycle 2 | 148 ± 25 | 748 ± 701 | 390 ± 319 | 265 ± 190 | 672 ± 336 | 242 ± 153 | 651 ± 605 |
The terminal-phase elimination half-life (t1/2,z) of motesanib was calculated as ln(2)/λz. The terminal elimination rate constant (λz) was determined by linear regression of the natural logarithms of at least the last 3 measurable concentrations during the terminal phase. For the 75 mg BID cohorts, t1/2,z is reported for the first daily dose.
| hours | Paclitaxel/Carboplatin + Motesanib 125 mg QD | Paclitaxel/Carboplatin + Motesanib 75 mg BID | Panitumumab + Motesanib 50 mg QD | Panitumumab + Motesanib 125 mg QD |
|---|---|---|---|---|
| Estimated Terminal-phase Half-life (t1/2,z) of Motesanib in Cycle 2 | 6.41 ± 2.08 | 6.36 ± 1.70 | 7.08 ± 0.35 | 4.90 ± 1.21 |
Area under the plasma concentration-time curve from time 0 to 24 hours post-dose (AUC0-24) for motesanib in Cycle 2 calculated using the using the linear/log trapezoidal method. For the 75 mg BID cohort AUC0-24 is the sum of AUC0-12 for the first and second daily dose.
| μg*hr/mL | Paclitaxel/Carboplatin + Motesanib 125 mg QD | Paclitaxel/Carboplatin + Motesanib 75 mg BID | Panitumumab + Motesanib 50 mg QD | Panitumumab + Motesanib 125 mg QD | Panitumumab + Paclitaxel/Carboplatin + Motesanib 125 mg QD |
|---|---|---|---|---|---|
| Area Under the Plasma Concentration-time Curve From Time 0 to 24 Hours Post-dose for Motesanib in Cycle 2 | 4.50 ± 2.62 | 3.11 ± 2.38 | 1.26 ± 0.61 | 3.92 ± 2.65 | 3.16 ± 1.20 |
The trough plasma concentration for motesanib at 24 hours postdose in Cycle 2. For the 75 BID cohort, C24 is the observed concentration at 24 hours (ie, after the second daily dose).
| ng/mL | Paclitaxel/Carboplatin + Motesanib 125 mg QD | Paclitaxel/Carboplatin + Motesanib 75 mg BID | Panitumumab + Motesanib 50 mg QD | Panitumumab + Motesanib 125 mg QD | Panitumumab + Paclitaxel/Carboplatin + Motesanib 125 mg QD |
|---|---|---|---|---|---|
| Trough Plasma Concentration at 24 Hours Post-dose (C24) for Motesanib in Cycle 2 | 43.4 ± 44.8 | 45.4 ± 35.9 | 10.4 ± 5.3 | 61.1 ± 72.6 | 45.1 ± 37.9 |
Collected over First dose through 30 days after last dose; maximum time on treatment was 322 days.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Paclitaxel/Carboplatin + Motesanib 50 mg QD | — | 5/6 (83.3%) | 6/6 (100%) |
| Paclitaxel/Carboplatin + Motesanib 125 mg QD | — | 2/11 (18.2%) | 11/11 (100%) |
| Paclitaxel/Carboplatin + Motesanib 75 mg BID | — | 3/6 (50%) | 6/6 (100%) |
| Panitumumab + Motesanib 50 mg QD | — | 0/4 (0%) | 4/4 (100%) |
| Panitumumab + Motesanib 125 mg QD | — | 1/7 (14.3%) | 7/7 (100%) |
| Panitumumab + Motesanib 75 mg BID | — | 4/5 (80%) | 5/5 (100%) |
| Panitumumab + Paclitaxel/Carboplatin + Motesanib 125 mg QD | — | 2/6 (33.3%) | 6/6 (100%) |
| Event | Paclitaxel/Carboplatin + Motesanib 50 mg QD | Paclitaxel/Carboplatin + Motesanib 125 mg QD | Paclitaxel/Carboplatin + Motesanib 75 mg BID | Panitumumab + Motesanib 50 mg QD | Panitumumab + Motesanib 125 mg QD | Panitumumab + Motesanib 75 mg BID | Panitumumab + Paclitaxel/Carboplatin + Motesanib 125 mg QD |
|---|---|---|---|---|---|---|---|
| CholecystitisHepatobiliary disorders | 0/6 | 0/11 | 1/6 | 0/4 | 0/7 | 2/5 | 0/6 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 2/6 | 0/11 | 0/6 | 0/4 | 0/7 | 0/5 | 0/6 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 2/6 | 0/11 | 0/6 | 0/4 | 0/7 | 0/5 | 1/6 |
| Abdominal painGastrointestinal disorders | 0/6 | 0/11 | 0/6 | 0/4 | 0/7 | 1/5 | 1/6 |
| DiarrhoeaGastrointestinal disorders | 0/6 | 0/11 | 0/6 | 0/4 | 0/7 | 1/5 | 0/6 |
| NauseaGastrointestinal disorders | 0/6 | 0/11 | 0/6 | 0/4 | 0/7 | 1/5 | 1/6 |
| VomitingGastrointestinal disorders | 0/6 | 0/11 | 0/6 | 0/4 | 0/7 | 1/5 | 0/6 |
| Staphylococcal sepsisInfections and infestations | 0/6 | 0/11 | 0/6 | 0/4 | 0/7 | 1/5 | 0/6 |
| AnorexiaMetabolism and nutrition disorders | 0/6 | 0/11 | 0/6 | 0/4 | 0/7 | 1/5 | 0/6 |
| Cognitive disorderNervous system disorders | 0/6 | 0/11 | 0/6 | 0/4 | 0/7 | 1/5 | 0/6 |
| Event | Paclitaxel/Carboplatin + Motesanib 50 mg QD | Paclitaxel/Carboplatin + Motesanib 125 mg QD | Paclitaxel/Carboplatin + Motesanib 75 mg BID | Panitumumab + Motesanib 50 mg QD | Panitumumab + Motesanib 125 mg QD | Panitumumab + Motesanib 75 mg BID | Panitumumab + Paclitaxel/Carboplatin + Motesanib 125 mg QD |
|---|---|---|---|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 3/6 | 7/11 | 6/6 | 0/4 | 5/7 | 3/5 | 5/6 |
| FatigueGeneral disorders | 5/6 | 8/11 | 4/6 | 2/4 | 6/7 | 5/5 | 5/6 |
| Dermatitis acneiformSkin and subcutaneous tissue disorders | 0/6 | 1/11 | 0/6 | 1/4 | 3/7 | 3/5 | 6/6 |
| PruritusSkin and subcutaneous tissue disorders | 1/6 | 2/11 | 0/6 | 0/4 | 6/7 | 3/5 | 3/6 |
| NauseaGastrointestinal disorders | 4/6 | 6/11 | 5/6 | 1/4 | 3/7 | 2/5 | 4/6 |
| VomitingGastrointestinal disorders | 4/6 | 4/11 | 5/6 | 0/4 | 1/7 | 4/5 | 1/6 |
| HypomagnesaemiaMetabolism and nutrition disorders | 1/6 | 5/11 | 5/6 | 2/4 | 3/7 | 4/5 | 2/6 |
| Exfoliative rashSkin and subcutaneous tissue disorders | 0/6 | 1/11 | 1/6 | 3/4 | 3/7 | 0/5 | 0/6 |
| StomatitisGastrointestinal disorders | 0/6 | 3/11 | 2/6 | 0/4 | 3/7 | 1/5 | 4/6 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 1/6 | 0/11 | 1/6 | 0/4 | 0/7 | 0/5 | 4/6 |
The analysis is based on the Safety Analysis Set which consists of all consented participants who received at least one dose of motesanib.
| Age, Continuous(years) | Paclitaxel/Carboplatin + Motesanib 50 mg QD | Paclitaxel/Carboplatin + Motesanib 125 mg QD | Paclitaxel/Carboplatin + Motesanib 75 mg BID | Panitumumab + Motesanib 50 mg QD | Panitumumab + Motesanib 125 mg QD | Panitumumab + Motesanib 75 mg BID | Panitumumab + Paclitaxel/Carboplatin + Motesanib 125 mg QD | Total |
|---|---|---|---|---|---|---|---|---|
| Mean | 67.8 ± 7.8 | 55.7 ± 12.7 | 64.5 ± 6.1 | 57.5 ± 9.9 | 64.0 ± 9.6 | 51.6 ± 14.6 | 59.0 ± 5.5 | 59.9 ± 10.8 |
| Sex: Female, Male(Participants) | Paclitaxel/Carboplatin + Motesanib 50 mg QD | Paclitaxel/Carboplatin + Motesanib 125 mg QD | Paclitaxel/Carboplatin + Motesanib 75 mg BID | Panitumumab + Motesanib 50 mg QD | Panitumumab + Motesanib 125 mg QD | Panitumumab + Motesanib 75 mg BID | Panitumumab + Paclitaxel/Carboplatin + Motesanib 125 mg QD | Total |
|---|---|---|---|---|---|---|---|---|
| Female | 0 | 4 | 3 | 0 | 5 | 1 | 3 | 16 |
| Male | 6 | 7 | 3 | 4 | 2 | 4 | 3 | 29 |
| Race/Ethnicity, Customized(participants) | Paclitaxel/Carboplatin + Motesanib 50 mg QD | Paclitaxel/Carboplatin + Motesanib 125 mg QD | Paclitaxel/Carboplatin + Motesanib 75 mg BID | Panitumumab + Motesanib 50 mg QD | Panitumumab + Motesanib 125 mg QD | Panitumumab + Motesanib 75 mg BID | Panitumumab + Paclitaxel/Carboplatin + Motesanib 125 mg QD | Total |
|---|---|---|---|---|---|---|---|---|
| White or Caucasian | 6 | 11 | 5 | 4 | 6 | 4 | 5 | 41 |
| Asian | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 2 |
| Black or African American | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 2 |
No study locations are listed for this record.
The record gives a start of Jan 2005, a primary completion of Mar 2007 and a completion of Mar 2007. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2014, 7 years after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Panitumumab
Carcinoma, Non-Small-Cell Lung →